News coverage about ChemoCentryx (NASDAQ:CCXI) has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. ChemoCentryx earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.5343982166997 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

A number of analysts have commented on CCXI shares. Zacks Investment Research upgraded ChemoCentryx from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Monday, July 17th. Cowen and Company restated a “hold” rating on shares of ChemoCentryx in a research report on Tuesday, August 8th. Finally, BidaskClub cut ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Friday, August 18th.

ChemoCentryx (NASDAQ:CCXI) traded up 1.53% during mid-day trading on Monday, hitting $7.32. The company had a trading volume of 158,401 shares. The company has a 50-day moving average price of $7.81 and a 200 day moving average price of $7.74. The firm’s market capitalization is $356.53 million. ChemoCentryx has a 12 month low of $4.57 and a 12 month high of $10.80.

ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.02). The company had revenue of $8.94 million during the quarter. Equities analysts forecast that ChemoCentryx will post ($0.90) EPS for the current fiscal year.

In related news, insider Petrus Bekker sold 65,509 shares of ChemoCentryx stock in a transaction dated Friday, June 30th. The stock was sold at an average price of $9.17, for a total value of $600,717.53. Following the completion of the transaction, the insider now owns 89,839 shares in the company, valued at approximately $823,823.63. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In the last 90 days, insiders sold 223,649 shares of company stock valued at $2,157,360. 26.80% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: This report was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at

ChemoCentryx Company Profile

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Insider Buying and Selling by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx Inc. and related companies with's FREE daily email newsletter.